The DOI matches its Crossref record, with a small difference in title or year; 15 of the 15 references it cites were found in a registry or an index.
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Open accessAbstract
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. Whether SGLT2 inhibitors are effective in patients with a higher left ventricular ejection fraction remains less certain. METHODS: We randomly assigned 6263 patients with heart failure and a left ventricular ejection fraction of more than 40% to receive dapagliflozin (at a dose of 10 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of worsening heart failure (which was defined as either an unplanned hospitalization for heart failure or an urgent visit for heart failure) or cardiovascular death, as assessed in a time-to-event analysis. RESULTS: Over a median of 2.3 years, the primary outcome occurred in 512 of 3131 patients (16.4%) in the dapagliflozin group and in 610 of 3132 patients (19.5%) in the placebo group (hazard ratio, 0.82; 95% confidence interval [CI], 0.73 to 0.92; P<0.001). Worsening heart failure occurred in 368 patients (11.8%) in the dapagliflozin group and in 455 patients (14.5%) in the placebo group (hazard ratio, 0.79; 95% CI, 0.69 to 0.91); cardiovascular death occurred in 231 patients (7.4%) and 261 patients (8.3%), respectively (hazard ratio, 0.88; 95% CI, 0.74 to 1.05). Total events and symptom burden were lower in the dapagliflozin group than in the placebo group. Results were similar among patients with a left ventricular ejection fraction of 60% or more and those with a left ventricular ejection fraction of less than 60%, and results were similar in prespecified subgroups, including patients with or without diabetes. The incidence of adverse events was similar in the two groups. CONCLUSIONS: Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction. (Funded by AstraZeneca; DELIVER ClinicalTrials.gov number, NCT03619213.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Risk of DKA is increased in persons using SGLT2is, especially in those being treated with insulin (especially if there has been a recent reduction in their insulin dose) and/or those with acute illnesses and prolonged fasting.1049,1050”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1049]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the EMPEROR-Preserved trial (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction) and DELIVER trial (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure), SGLT2 inhibition reduced the risk of cardiovascular death and worsening HF events by 18% to 21%4,5 and improved KCCQ-CSS by 1.5 to 2.3 points”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SGLT2 inhibitors reduce the incidence of heart failure and improve heart failurerelated outcomes, including hospitalization for heart failure and heart failure-related symptoms, in people with diabetes with preserved or reduced ejection fraction (250,(255)(256)(257)(298)(299)(300)(301)(302)(303)(304)(305)(306).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [302]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“A similar benefit for heart failure outcomes was seen in the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial for dapagliflozin in people with mildly reduced or preserved ejection fraction (302).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [302]
The cited source says what the claim attributes to it.
In the citing paper
“A similar benefit for heart failure outcomes was seen in the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial for dapagliflozin in people with mildly reduced or preserved ejection fraction (290).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [290]
In the citing paper
“Sacubitril/valsartan, compared with valsartan, reduced the likelihood of the primary composite outcome of CV death and total HF hospitalization by 22% in those with an LVEF below or equal to the median of 57%.534”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [534]
In the citing paper
“Over the past decade, several large RCTs failed to achieve statistical significance with regard to effects on the primary outcomes in patients with HFpEF including: PEP-CHF (perindopril), CHARM-Preserved (candesartan), I-PRESERVE (irbesartan), TOPCAT (spironolactone), DIG Ancillary Trial (digoxin), and PARAGON-HF (sacubitril/valsartan). 477,[534][535][536][537][538]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [534]
In the citing paper
“DELIVER recruited 6263 patients with heart failure with mildly reduced or preserved (>40%) ejection fraction including 3109 patients without diabetes.”
In the citing paper
“There is good evidence to support the use of SGLT2 inhibitors as a foundational therapy to prevent cardiovascular death or hospitalisation for heart failure in patients with heart failure, irrespective of ejection fraction or history of previous diabetes.1, 2, 3, 4, 5”
In the citing paper
“Large placebo-controlled trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of cardiovascular disease, and particularly hospitalisation for heart failure, in patients with type 2 diabetes at high risk of atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.”
In the citing paper
“Since 2021, two placebo-controlled SGLT2 inhibitor trials (EMPA-KIDNEY and DELIVER) have studied a large number of people without diabetes.”
In the citing paper
“Approximately 44% of patients randomized to either dapaglifl ozin or placebo had type 2 diabetes, and results were consistent regardless of the presence of type 2 diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [199]
In the citing paper
“The primary outcome of a composite of worsening heart failure, de fi ned as hospitalization or urgent visit for heart failure, or cardiovascular death was reduced by 18% in patients treated with dapagli fl ozin compared with placebo (HR 0.82 [95% CI 0.73 -0.92]; P < 0.001).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationDapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citation2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Self-citationAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationCategorical Data Analysis Using the SAS System
Ziegel, E. R., Stokes, M., Davis, C., & Koch, G. (1996) · Technometrics · doi:10.1080/00401706.1996.10484575 · Cited by 2,034
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033502 · Cited by 750
Self-citationSolomon, S. D., Claggett, B. L., Lewis, E. F., Desai, A. S., Anand, I. S., Sweitzer, N. K., O’Meara, E., Shah, S. J., McKinlay, S. M., Fleg, J. L., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv464 · Cited by 538
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,002
Xanthopoulos, A. V., Christofidis, C., Pantsios, C., Magouliotis, D. E., Bourazana, A., Leventis, I., Skopeliti, N., Skoularigki, E., Briasoulis, Α., Giamouzis, G., et al. (2023) · Life · doi:10.3390/life13030698 · Cited by 10
Wahinya, M., & Khan, Z. U. (2023) · Cureus · doi:10.7759/cureus.37388 · Cited by 10
Renal Oxygen Demand and Nephron Function: Is Glucose a Friend or Foe?
Gronda, E., Iacoviello, M., Palazzuoli, A., Benevenuto, M., Gabrielli, D., & Arduini, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129957 · Cited by 13
Hammer, A., Hofer, F., Kazem, N., Koller, L., Steinacher, E., Baumer, U., Wollmann, F., Kautzky‐Willer, A., Beitl, K., Remer, F., et al. (2023) · Journal of Women s Health · doi:10.1089/jwh.2023.0059 · Cited by 10
Butt, J. H., Jering, K., de Boer, R. A., Claggett, B. L., Desai, A. S., Hernandez, A. F., Inzucchi, S. E., Jhund, P. S., Køber, L., Kosiborod, M., et al. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.08.027 · Cited by 11
Self-citationTheodorakopoulou, M. P., Alexandrou, M. E., Tsitouridis, A., Kamperidis, V., Pella, E., Xanthopoulos, A. V., Ziakas, A., Triposkiadis, F. K., Vassilikos, V. P., Papagianni, A. A., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae003 · Cited by 11
Kim, J., Yoon, Y., Kim, Y., Park, J., Choi, K., Nam, J., Lee, C., Son, J., Park, J., & Kim, U. (2024) · Clinical Cardiology · doi:10.1002/clc.24248 · Cited by 10
Liu, C., Ho, Y., Lee, W., Huang, C., Lee, Y., Hsieh, C., Huang, N., Wu, C., Nguyen, N. U. N., Hsu, C., et al. (2024) · Environmental Toxicology · doi:10.1002/tox.24362 · Cited by 10
RetractedWang, Q., Yu, J., Deng, W., Liu, C., Yang, J., Li, Y., Cai, G., Chen, X., & Dong, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1372421 · Cited by 10
Yang, M., Kondo, T., Anand, I. S., de Boer, R. A., Campbell, R. T., Køber, L., Lam, C. S. P., Maggioni, A. P., Martínez, F. A., O’Meara, E., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3417 · Cited by 11
Self-citationSorimachi, H., Obokata, M., Omote, K., Reddy, Y. N. V., Burkhoff, D., Shah, S. J., & Borlaug, B. A. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.08.042 · Cited by 11
Self-citationAa, B., Serova, M., Chashkina, M. I., Kosharnaia, R. S., Salpagarova, Z. K., Andreev, D. A., & Giverts, I. (2024) · Cardiac failure review · doi:10.15420/cfr.2024.06 · Cited by 10
Mori, Y., Komura, T., Adomi, M., Yagi, R., Fukuma, S., Kondo, N., Yanagita, M., Duru, O. K., Tuttle, K. R., & Inoue, K. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02478-7 · Cited by 12
Sinclair, M. R., Ardehali, M. M., Diamantidis, C. J., & Corsino, L. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1412874 · Cited by 10
Metabolic acidosis in patients with diabetes 2 undergoing cardiac surgery
Brekke, H. K., Holmaas, G., Astor, M. C., Steien, E., Haaverstad, R., Ghavidel, F. Z., & Farstad, M. (2024) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000002090 · Cited by 10
Liu, H., Jiang, B., Hua, R., Liu, X., Qiao, B., Zhang, X., Liu, X., Wang, W., Yuan, Q., Wang, B., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02477-8 · Cited by 10
Early pathological mechanisms in a mouse model of heart failure with preserved ejection fraction
Rosas, P. C., Neves, L. A. A., Patel, N. A., Tran, D., Pereira, C. H., Bonilla, K., Zheng, J., Sun, J., Alvarado, F. J., & Banach, K. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00318.2024 · Cited by 11
New and future heart failure drugs
Haghighat, L., DeJong, C., & Teerlink, J. R. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00576-z · Cited by 14
Left bundle branch block—Innocent bystander, silent menace, or both
Lau, E. W., Bonnemeier, H., & Baldauf, B. J. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.12.038 · Cited by 11
Bellos, I., Marinaki, S., Λάγιου, Π., & Benetou, V. (2024) · Biomolecules · doi:10.3390/biom15010039 · Cited by 10
Merlo, A., D’Elia, E., Odoardo, L. A. F. D., Sciatti, E., & Senni, M. (2024) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae117 · Cited by 10
Sotomayor-Julio, A. D., Seni-Molina, S., Gutiérrez‐Posso, J. M., Muñoz-Ordoñez, J. A., Azcárate-Rodríguez, V., León-Giraldo, H., Perna, E. R., Rossel, V., Quesada-Chaves, D., Speranza, M., et al. (2025) · Global Heart · doi:10.5334/gh.1418 · Cited by 10
Noiri, J., Fujimoto, W., Takemoto, M., Kuroda, K., Yamashita, S., Imanishi, J., Iwasaki, M., Todoroki, T., Okuda, M., Nagao, M., et al. (2025) · Circulation Reports · doi:10.1253/circrep.cr-25-0002 · Cited by 11
Kondo, T., Jhund, P. S., Henderson, A. D., Claggett, B. L., Desai, A. S., BRINKER, M. D., Lay‐Flurrie, J., Schloemer, P., Viswanathan, P., Amarante, F., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3669 · Cited by 10
Self-citationXu, Z., Li, X., Mi, X., & Lin, Y. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144166 · Cited by 10
Meekers, E. M., Martens, P., Knevels, R., Miseur, M., Ezzat, A., Croset, F., Dauw, J., Gruwez, H., Dhont, S., Erzeel, J., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3693 · Cited by 10
Self-citationOzaki, Y., Uemura, Y., Kondo, T., Kazama, S., Yamaguchi, S., Okajima, T., Mitsuda, T., Ishikawa, S., Takemoto, K., Okumura, T., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0092 · Cited by 11
Clinical Phenotyping and Treatment Response in Patients With Chronic Heart Failure
Tatsuta, D., Nakao, M., Nagai, T., Mizuguchi, Y., Yokota, I., Koya, T., Tada, A., Ishizaka, S., George, F., Kato, Y., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101972 · Cited by 12
Borlaug, B. A., Zile, M. R., Kramer, C. M., Litwin, S. E., Ye, W., Ou, Y., Hurt, K. C., Murakami, M., & Packer, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf663 · Cited by 11
Xia, J., Nong, Y., Teng, J., Mohammed, S. A., Liu, J., Pang, Y., Costantino, S., Ruschitzka, F. T., Hamdani, N., Abdellatif, M., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113471 · Cited by 12
The use of SGLT2 inhibitors in older people: What is important?
Armentaro, G., Maio, R., Bencivenga, L., Okoye, C., Severini, G., Cassano, V., Zanobbi, V., Condoleo, V., Bellelli, G., Rengo, G., et al. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-03156-8 · Cited by 10
Olagunju, A., Yamani, N., Kenny, D., Mookadam, M., Mookadam, F., & Unzek, S. (2022) · World Journal of Cardiology · doi:10.4330/wjc.v14.i11.599 · Cited by 11
Elkammash, A., Tam, S. S. C., Yogarajah, G., & You, J. (2023) · Cureus · doi:10.7759/cureus.35030 · Cited by 12
Lv, J., Guo, L., Wang, R., & Chen, J. (2023) · Kidney Diseases · doi:10.1159/000530395 · Cited by 12
Riccardi, M., Sammartino, A. M., Adamo, M., Inciardi, R. M., Lombardi, C., Pugliese, N. R., Tomasoni, D., Vizzardi, E., Metra, M., Coats, A. J. S., et al. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10315-4 · Cited by 10
Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure—Current Evidence in Special Populations
Moady, G., Gal, T. B., & Atar, S. (2023) · Life · doi:10.3390/life13061256 · Cited by 10
Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease
Oikonomou, E. K., Xenou, M., Zakynthinos, G. Ε., Tsaplaris, P., Lampsas, S., Bletsa, E., Gialamas, I., Kalogeras, K. I., Goliopoulou, A., Gounaridi, M. I., et al. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230703161058 · Cited by 11
Sevre, K., Rist, A., Wachtell, K., Devereux, R. B., Aurigemma, G. P., Smiseth, O. A., Kjeldsen, S. E., Julius, S., Pitt, B., Burnier, M., et al. (2023) · American Journal of Hypertension · doi:10.1093/ajh/hpad073 · Cited by 10
Practical Guidance for the Use of SGLT2 Inhibitors in Heart Failure
Cavallari, I., Crispino, S. P., Segreti, A., Ussia, G. P., & Grigioni, F. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00601-9 · Cited by 13
Exploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effect—What Is New in 2023?
Young, C. F., Farnoudi, N., Chen, J., & Shubrook, J. H. (2023) · Endocrines · doi:10.3390/endocrines4030045 · Cited by 14
Tanaka, A., Kinugawa, K., Kuwahara, K., Ito, H., Murohara, T., Hirata, K., Node, K., & on behalf of administrative board members of the Japanese Circulation Society and the Japanese Heart Failure Society (2023) · Circulation Journal · doi:10.1253/circj.cj-23-0605 · Cited by 10
Escobar, C., Pascual-Figal, D. A., Manzano, L., Núñez, J. E., & Camafort, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216798 · Cited by 10
Wester, M., Arzt, M. E., Sinha, F., Maier, L. S., & Lebek, S. (2023) · Biomedicines · doi:10.3390/biomedicines11113038 · Cited by 10
SGLT2 inhibitors in heart failure with preserved ejection fraction
Faluk, M. A., Wardhere, A., Thakker, R. A., & Khan, F. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102388 · Cited by 11
Bedros, J. R., Jermendy, G., Gaál, Z., Gerő, L., Hídvégi, T., Kempler, P., Lengyel, C., Várkonyi, T. T., Winkler, G., & Wittmann, I. (2023) · Diabetologia Hungarica · doi:10.24121/dh.2023.20 · Cited by 18
Fardman, A., Kodesh, A., Siegel, A. J., Segev, A., Regev, E., Maor, E., Berkovitch, A., Kuperstein, R., Morgan, A., Nahum, E., et al. (2024) · Artificial Organs · doi:10.1111/aor.14733 · Cited by 10
Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon
Lucà, F., Oliva, F. G., Abrignani, M. G., Fusco, S. A. D., Gori, M., Giubilato, S., Ceravolo, R., Temporelli, P. L., Cornara, S., Rao, C. M., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051375 · Cited by 14
Targeting obesity for therapeutic intervention in heart failure patients
Sato, R., & von Haehling, S. (2024) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2024.2363395 · Cited by 10
SGLT-2 inhibitors in heart failure and chronic kidney disease: A review for internists
Jaswaney, R., Sokoloff, S., Rakita, V., & Rubin, D. J. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23093 · Cited by 12
Torsemide comparison with furosemide for management of heart failure (TRANSFORM-HF) trial
Verbrugge, F. H., & Menon, V. (2022) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuac144 · Cited by 10
Jensen, J., Poulsen, M. K., Petersen, P. W., Gerdes, B., Rossing, K., & Schou, M. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14324 · Cited by 11
Hsu, C., Hsuan, C., Liao, D., Chang, J. K.-J., Chang, A. J.-W., Hee, S., Lee, H.-L., & Teng, S. I. F. (2023) · Life · doi:10.3390/life13041024 · Cited by 11
DELIVERing Therapeutic Efficacy Across the Ejection Fraction Spectrum of Heart Failure
Lam, C. S. P., & Solomon, S. D. (2022) · Circulation · doi:10.1161/circulationaha.122.062022 · Cited by 10
Self-citationMebazaa, A., Solal, A. C., & Colombo, P. C. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac680 · Cited by 10
Jack, G. A., Avenatti, E., Kashyap, S. R., & Sadhu, A. R. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf301 · Cited by 9
Matsukawa, R., Okahara, A., Tokutome, M., Itonaga, J., Hara, A., Kisanuki, H., Sada, M., Okabe, K., Kawai, S., Matsuura, H., et al. (2023) · Circulation Reports · doi:10.1253/circrep.cr-22-0118 · Cited by 10
Keidai, Y., Yoshiji, S., Hasebe, M., Minamino, H., Murakami, T., Tanaka, D., Fujita, Y., & Inagaki, N. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15122 · Cited by 12
Contemporary Approach to Tricuspid Regurgitation: Knowns, Unknowns, and Future Challenges
Samim, D., Dernektsi, C., Brugger, N., Reineke, D., & Praz, F. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.11.041 · Cited by 9
SGLT2 inhibitors and the cardiac rhythm: unraveling the connections
Paul, A., Tabaja, C., & Wazni, O. M. (2024) · International Journal of Arrhythmia · doi:10.1186/s42444-024-00109-6 · Cited by 9
ELUCIDATE Trial: A Single‐Center Randomized Controlled Study
Lin, J., Liu, S.-C., Liu, T., Chuang, S., Huang, C., Chen, Y.-J., Lee, C., Chien, M.-N., Hou, C. J., Yeh, H., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033832 · Cited by 9
Self-citationDuvalyan, A., Hoz, R. M. L., McGuire, D. K., & Drazner, M. H. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.04.009 · Cited by 9
Soltani, F., Jenkins, D. A., Kaura, A., Bradley, J., Black, N., Farrant, J. P., Williams, S. G., Mulla, A., Glampson, B., Davies, J., et al. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-03987-9 · Cited by 9
Value of the triglyceride–glucose index and related parameters in heart failure patients
Fang, Y., Shen, J., & Lyu, L. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1397907 · Cited by 9
Tran, B. A., White, R. T., Bullers, K., & Cornelio, C. K. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225241261040 · Cited by 9
Wang, X., He, M., Jin, D., Sun, C., & Lu, H. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01446-1 · Cited by 10
Litwin, S. E., Komtebedde, J., Borlaug, B. A., Kaye, D. M., Hasenfuβ, G., Kawash, R., Hoendermis, E. S., Hummel, S. L., Čikeš, M., Gustafsson, F., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.08.014 · Cited by 9
Self-citationPabón, M. A., Vaduganathan, M., Claggett, B. L., Chatur, S., Siqueira, S., Castellote, P.-M. M., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3410 · Cited by 10
Self-citationSupranormal Left Ventricular Ejection Fraction, Concentric Remodeling, and Long-Term Survival
Chang, H., Tseng, C., Huang, W., Lee, C., YU, W., Cheng, H., Chiang, C., Chen, C.-H., & Sung, S. (2024) · JACC Asia · doi:10.1016/j.jacasi.2024.08.020 · Cited by 9
Self-citationOstrominski, J. W., Lassen, M. C. H., Claggett, B. L., Miao, Z. M., Inzucchi, S. E., Docherty, K. F., Desai, A. S., Jhund, P. S., Køber, L., Ponikowski, P. P., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae780 · Cited by 9
Self-citationRaja, A., Dogar, M., Raja, S., Shuja, M. H., Amin, S. B., Khelani, M., Fatima, U., Soomro, A., Habiba, A., Mustafa, I., et al. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04412-x · Cited by 10
Inflammation in Heart Failure: Mechanisms and Therapeutic Strategies
Jiang, Y., Zhou, G., Guo, Y., & Long, Y. (2024) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2024.0050 · Cited by 15
Zhou, L., Niu, M., Chen, W. J., Hu, Q., Chen, Y., Geng, X., & Gu, J. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1490316 · Cited by 9
Siriwardana, A. N., Buizen, L., Jun, M., Kotwal, S. S., Arnott, C. G., Jardine, M., Levin, A., Heerspink, H. J. L., Charytan, D. M., Pollock, C. A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16190 · Cited by 9
Zhou, Z., Wang, S., Fan, Z., Zhang, Z., Zhang, X., Zhao, Z., Wang, X., & Mao, J. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156530 · Cited by 9
Anti-inflammatory Therapies for Ischemic Heart Disease
Muhs, T., Ljubojević-Holzer, S., & Sattler, S. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02211-0 · Cited by 9
Sex differences in diagnosis and treatment of heart failure: toward precision medicine
Lee, S. Y., & Park, S. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.338 · Cited by 9
Feng, Q., Wu, M., & Mai, Z. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1482918 · Cited by 12
Venema, C. S., van Bergeijk, K. H., Krikken, J. A., van der Werf, H. W., van den Heuvel, A. F. M., Douglas, Y. L., Mordi, I. R., Girerd, N., Lang, C. C., Lam, C. S. P., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038786 · Cited by 9
Self-citationFerreira, J. P., Vasques‐Nóvoa, F., Saraiva, F. A., Oliveira, A., Almeida, J., Batista, A. B., Barbosa, A., Ferreira, A. F., Costa, C., Santos‐Ferreira, D., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15294 · Cited by 9
Gliflozins in hypertension: basic mechanisms and clinical insights
Rieg, T., Liu, R., & Staruschenko, A. (2025) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00119.2025 · Cited by 10
Chiang, C., Wang, K.-L., Cheng, H., Chao, T., & Sung, S. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001263 · Cited by 9
Self-citationRepurposing metabolic drugs as anti-inflammatory agents
Hogan, A. E., Davis, C., Jenkins, B., Jones, N., & O'Shea, D. B. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.07.003 · Cited by 14
Ostrominski, J. W., Neuen, B. L., Claggett, B. L., Anand, I. S., Desai, A. S., Jhund, P. S., Lam, C. S. P., Pfeffer, M. A., Pitt, B., Zannad, F. M., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.028 · Cited by 9
Self-citationMineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis
Zhang, Y., Bao, Y.-C., Wang, L.-X., Zhao, H.-J., Sun, J., Sun, L., Duan, W., Du, M., Wang, L., An, Q.-Y., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1667236 · Cited by 10
Greco, A., Quagliariello, V., Rizzo, G., Tedeschi, A., Schirinzi, S., Turco, A., Galiazzo, M. C., Acquaro, M., Amicis, M. D., Klersy, C., et al. (2025) · Cardio-Oncology · doi:10.1186/s40959-025-00368-9 · Cited by 9
Singh, Y. S., Matsue, Y., Iso, T., Fujimoto, Y., Yanagisawa, N., Shitara, J., Suwa, S., Miyakuni, S., Mizukami, A., Saito, Y., et al. (2025) · Journal of Cardiology · doi:10.1016/j.jjcc.2025.09.011 · Cited by 9
Salah, H. M., Ambrosy, A. P., Biegus, J., Bocchi, E. A., Butler, J., Chioncel, O. D., Cotter, G., Davison, B. A., Dzudié, A., Freund, Y., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.09.020 · Cited by 10
Chioncel, O., Savarese, G., Laroche, C., Amir, O., Tokmakova, M. P., Cannata, A. N., Do, D. L., Kafafy, T. A., Krejčí, J., Moura, B., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70065 · Cited by 9
Advances in the Pharmacological Treatment of Heart Failure With Preserved Ejection Fraction
Valente, V., Beer, B. N., & Savarese, G. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2025.0111 · Cited by 9
Ito, N., Zen, K., Takahara, M., Tani, R., Nakamura, S., Fujimoto, T., Takamatsu, K., Yashige, M., Kadoya, Y., Yamano, M., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14305 · Cited by 9
Martínez, J. J. G., Ferreira-Ocampo, P. J., Sanz-Pastor, A. G., Cárdenas‐Salas, J., Antón-Bravo, T., Brito-Sanfiel, M. Á., & Ruiz, F. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134248 · Cited by 9
Hardin, K. M., Giverts, I., Campain, J., Farrell, R., CUNNINGHAM, T., Brooks, L. C., Christ, A. M., Wooster, L. T., Bailey, C. S., Schoenike, M., et al. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.05.023 · Cited by 9
Gaps in Modern Heart Failure and Chronic Kidney Disease Research
Parmar, S. S., Muthuppalaniappan, V. M., & Banerjee, D. (2023) · European Cardiology Review · doi:10.15420/ecr.2022.64 · Cited by 9
Chipayo-Gonzales, D., Shabbir, A., Vergara-Uzcategui, C. E., y, L. N.-F., Jiménez‐Quevedo, P., Gonzalo, N., Nuñez-Gil, I. J., Mejía-Rentería, H. D., Macaya‐Ten, F., Tirado‐Conte, G., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01454-w · Cited by 9
Quality of life in heart failure: New data, new drugs and devices
Major, K., Bodys-Pełka, A., Grabowski, M., & Lelonek, M. (2023) · Cardiology Journal · doi:10.5603/cj.92243 · Cited by 9
Rationale and design of the United Kingdom Heart Failure with Preserved Ejection Fraction Registry
UK HFpEF Collaborative Group (2023) · Heart · doi:10.1136/heartjnl-2023-323049 · Cited by 9
Erhardsson, M., Faxén, U. L., Venkateshvaran, A., Svedlund, S., Saraste, A., Fermer, M. L., Gan, L., Shah, S. J., Tromp, J., Lam, C. S. P., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14569 · Cited by 9
Self-citationYoshihara, F., Imazu, M., Sakuma, I., Hiroi, Y., Hara, H., Okazaki, O., Ishiguro, C., Izumi, C., Noguchi, T., Shiraiwa, T., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102334 · Cited by 9
Self-citationMedical Management and Device-Based Therapies in Chronic Heart Failure
Nguyen, A. H., Hurwitz, M., Abraham, J. A., Blumer, V. L., Flanagan, M. C., Garan, A. R., Kanwar, M. K., Kataria, R., Kennedy, J. L. W., Kochar, A., et al. (2023) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2023.101206 · Cited by 10
Naito, A., Nagatomo, Y., Kawai, A., Iwashita, M., Nakazawa, R., Taruoka, A., Takefuji, A., Yasuda, R., Toya, T., Ikegami, Y., et al. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14020141 · Cited by 10
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., Jhund, P. S., Belohlavek, J., Chiang, C.-E., Borleffs, C. J. W., Comin-Colet, J., Dobreanu, D., Drozdz, J., Fang, J. C., Alcocer-Gamba, M. A., Al Habeeb, W., Han, Y., Cabrera Honorio, J. W., Janssens, S. P., Katova, T., Kitakaze, M., Merkely, B., O’Meara, E., Saraiva, J. F. K., Tereshchenko, S. N., Thierer, J., Vaduganathan, M., Vardeny, O., Verma, S., Pham, V. N., Wilderäng, U., Zaozerska, N., Bachus, E., Lindholm, D., Petersson, M., & Langkilde, A. M.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (S.D.S., B.C., A.S.D., M.V.); the British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom (J.J.V.M., P.S.J.); the Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen (R.A.B., C.S.P.L.), and Haga Teaching Hospital, the Hague (C.J.W.B.) — both in the Netherlands; the University of Wisconsin, Madison (D. DeMets); Duke University Medical Center, Durham, NC (A.F.H.); Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri, Kansas City, Kansas City (M.N.K.); National Heart Center Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); National University of Cordoba, Cordoba (F.M.), and Jefe de Unidad de Insuficiencia Cardíaca, Centro de Educación Médica e Investigaciones Clínicas Norbert...
- Northwestern University (US)
- Semmelweis University (HU)
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Claggett, Brian
- de Boer, Rudolf A.
- DeMets, David
- Hernandez, Adrian F.
- Inzucchi, Silvio E.
- Kosiborod, Mikhail N.
- Lam, Carolyn S.P.
- Shah, Sanjiv J.
- Desai, Akshay S.
- Jhund, Pardeep S.
- Chiang, Chern-En
- Dobreanu, Dan
- Fang, James C.
- Alcocer-Gamba, Marco Antonio
- Han, Yaling
- Janssens, Stefan P.
- Kitakaze, Masafumi
- Merkely, Béla
- O’Meara, Eileen
- Tereshchenko, Sergey N.
- Thierer, Jorge
- Vaduganathan, Muthiah
- Vardeny, Orly
- Verma, Subodh
- Pham, Vinh Nguyen
- Wilderäng, Ulrica
- Bachus, Erasmus
- Lindholm, Daniel
- Petersson, Magnus
- Langkilde, Anna Maria
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-09-22
- Volume
- 387
- Issue
- 12
- Pages
- 1089-1098
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4293354639
- Cited by
- 2,884
- References
- 15
- Citations by year
- 2026: 635 · 2025: 716 · 2024: 714 · 2023: 673 · 2022: 139
- FWCI
- 390.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
- Lirias (KU Leuven) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- dapagliflozin, SGLT2 inhibitors, heart failure, preserved ejection fraction, mildly reduced ejection fraction, heart failure hospitalization, cardiovascular mortality, left ventricular ejection fraction
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucosides, Heart Failure, Humans, Stroke Volume, Ventricular Function, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
